Belite Bio Reports Third Quarter 2023 Operational

Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11...

Related Keywords

France ,Phoenix ,Arizona ,United States ,China ,Taiwan ,Netherlands ,Westmead ,New South Wales ,Australia ,Belgium ,Hong Kong ,United Kingdom ,Germany ,Switzerland ,Sydney ,American ,John Grigg ,Tom Lin ,Belite Bio ,Jennifer Wu ,University Of Sydney ,Company Adss ,Drug Administration ,Twitter ,Instagram ,Linkedin ,Exchange Commission ,Facebook ,Belite Bio Inc ,American Association Of Ophthalmology ,Sydney Children Hospitals Network At Westmead ,Geographic Atrophy ,Webcast Tuesday ,Stargardt Disease ,Head Specialty ,Consultant Ophthalmologist ,Sydney Children ,Hospitals Network ,Sydney Eye Hospital ,American Association ,Upcoming Milestones ,Age Related Macular Degeneration ,Fast Track ,Rare Pediatric Disease ,Progstar Cohort ,Star Report ,Revenue Code ,Mark To Market Election ,Investor Relations Contact ,Nasdaq Blte ,Nc ,